<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OLSALAZINE SODIUM</span><br/>(ol-sal'a-zeen)<br/><span class="topboxtradename">Dipentum<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal</span>; <span class="classification">mucous membrane antiinflammatory agent</span><br/><b>Prototype: </b>Mesalamine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Converted to 5-aminosalicylic acid (5-ASA) by colonic bacteria. The 5-ASA is absorbed slowly, resulting in a very high local
         concentration in the colon.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The 5-ASA has antiinflammatory activity in ulcerative colitis.</p>
<h1><a name="uses">Uses</a></h1>
<p>Maintenance therapy in patients with ulcerative colitis.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Acute flare-up of ulcerative colitis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to salicylates.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with preexisting kidney disease; pregnancy (category C). It is not known whether it is excreted in breast milk. Safety
         and effectiveness in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Ulcerative Colitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 500 mg b.i.d., may increase up to 1.53 g/d in 24 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food in two evenly divided doses.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache. <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea,</span> nausea, abdominal pain, indigestion, vomiting, bloating. <span class="typehead">Skin:</span> Rash. <span class="typehead">Body as a Whole:</span> Arthralgia. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 13% absorbed from GI tract; high colonic concentrations are associated with efficacy. <span class="typehead">Metabolism:</span> Olsalazine, a prodrug, is composed of 2 molecules of 5-ASA, the proposed active antiinflammatory agent, connected by an azo
      bond; colonic bacterial azo-reductases break the azo bond, thus releasing 2 active molecules of 5-ASA. <span class="typehead">Elimination:</span> Primarily eliminated in feces as 5-ASA. <span class="typehead">Half-Life:</span> At least 6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor kidney function in patients with preexisting renal disease.</li>
<li>Monitor for S&amp;S of a hypersensitivity reaction (see Appendix F). Withhold olsalazine and notify physician at first sign of
            an allergic response.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report diarrhea, a possible adverse effect, to the physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>